4 commercial payer policies list J1413. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
4 policies from 4 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of J1413 |
|---|---|---|
| Gene Therapy for Duchenne Muscular Dystrophy | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J1413 |
|---|---|---|
| Elevidys (Delandistrogene Moxeparvovec-Rokl) | Mar 1, 2026 | Covered |
| Policy | Effective | Status of J1413 |
|---|---|---|
| Elevidys (Delandistrogene Moxeparvovec-Rokl) | Mar 1, 2026 | Covered |
| Policy | Effective | Status of J1413 |
|---|---|---|
| Elevidys (Delandistrogene Moxeparvovec-Rokl) | Mar 1, 2026 | Covered |